TheraCryf PLC (LSE:TCF), the addiction and neuropsychiatry drug developer listed on London's AIM market, has taken another step towards human trials for its lead candidate. In an announcement on 2 October 2026, the company said its wholly owned subsidiary, TheraCryf Australia Pty Ltd, had appointed contract research organisation Avance Clinical to support a first-in-human Phase 1 study of Ox-1. The update followed annual results for the year to 31 March 2026, published on 28 September, and a small fundraising completed in September.

What TheraCryf Does

TheraCryf is a biotechnology company based at Alderley Park in Cheshire. It develops medicines for addiction and other neuropsychiatric disorders using a capital-light, virtual model, aiming to advance programmes to early clinical or proof-of-concept stage before partnering them with larger pharmaceutical or biotech groups.

Its lead asset, Ox-1, is a selective orexin-1 receptor antagonist being developed for addiction and related conditions, including binge eating, alcohol use and other substance use disorders. A second programme, a dopamine transporter (DAT) modulator, targets fatigue of brain origin, such as fatigue linked to multiple sclerosis, chemotherapy and narcolepsy. A legacy, grant-funded glioblastoma programme uses SFX-01.

Latest Developments

Avance Clinical was selected after a competitive process. Its remit covers the application to a Human Research Ethics Committee and a Clinical Trial Notification to Australia's Therapeutic Goods Administration. TheraCryf said it is targeting approval to proceed with clinical use of Ox-1 in Australia by 31 December 2026, subject to ethics and trial-site approvals. Final GLP toxicology data are expected in early Q4 2026, and GMP manufacture of the drug substance has been completed. No contract value was disclosed.

According to the annual results, Ox-1 completed late-stage preclinical development on schedule and on budget, and dose-range-finding studies showed no adverse observations up to the regulatory maximum. After the year end, the company completed GMP manufacture of 2.57kg of drug substance, reported top-line data from a first-species toxicology study showing a wide safety margin, and started a second-species study. It also rejected a non-binding proposal for the Ox-1 and DAT programmes, which the board said significantly undervalued the business.

Financial Picture

For the year to 31 March 2026, TheraCryf reported a post-tax loss of about £3.5 million, compared with £1.9 million a year earlier, as external R&D spending rose to roughly £1.5 million. Cash, short-term investments and deposits fell to around £1.5 million from £4.1 million. The auditor's report included a material uncertainty in relation to going concern, and the company acknowledged that further funding will be required.

In a placing and subscription announced on 20 August 2026 and approved at a general meeting in early September, TheraCryf raised £1.05 million gross at 0.18p per share. The proceeds are intended to complete clinic-enabling work and extend the cash runway to the end of Q1 2027. The company does not pay a dividend.

Sector and index Context

TheraCryf is one of many early-stage life sciences names within the FTSE AIM All Share Index, where companies often rely on periodic Equity raises to fund research until partnering deals or licensing income arrive.

Key Risks

The main risks are financial and clinical. The Going Concern uncertainty and short runway mean further dilution is likely unless a partnering transaction is agreed. Regulatory timelines in Australia could slip, and safety or efficacy findings in human studies may differ from preclinical data. A dispute with former SFX-01 partner Stalicla SA was described as progressing slowly, with talks ongoing.

What to Watch Next

Investors will be looking for final GLP toxicology data, the outcome of the ethics and regulatory submissions in Australia ahead of the year-end target, any progress in partnering discussions, and the company's plans for funding beyond the first quarter of 2027.